Style | Citing Format |
---|---|
MLA | Khalighfard S, et al.. "A Systematic Approach Introduced Novel Targets in Rectal Cancer by Considering Mirna/Mrna Interactions in Response to Radiotherapy." Cancer Biomarkers, vol. 33, no. 1, 2022, pp. 97-110. |
APA | Khalighfard S, Kalhori MR, Amiriani T, Poorkhani A, Khori V, Esmati E, Lashkari M, Najafi A, Alizadeh AM (2022). A Systematic Approach Introduced Novel Targets in Rectal Cancer by Considering Mirna/Mrna Interactions in Response to Radiotherapy. Cancer Biomarkers, 33(1), 97-110. |
Chicago | Khalighfard S, Kalhori MR, Amiriani T, Poorkhani A, Khori V, Esmati E, Lashkari M, Najafi A, Alizadeh AM. "A Systematic Approach Introduced Novel Targets in Rectal Cancer by Considering Mirna/Mrna Interactions in Response to Radiotherapy." Cancer Biomarkers 33, no. 1 (2022): 97-110. |
Harvard | Khalighfard S et al. (2022) 'A Systematic Approach Introduced Novel Targets in Rectal Cancer by Considering Mirna/Mrna Interactions in Response to Radiotherapy', Cancer Biomarkers, 33(1), pp. 97-110. |
Vancouver | Khalighfard S, Kalhori MR, Amiriani T, Poorkhani A, Khori V, Esmati E, et al.. A Systematic Approach Introduced Novel Targets in Rectal Cancer by Considering Mirna/Mrna Interactions in Response to Radiotherapy. Cancer Biomarkers. 2022;33(1):97-110. |
BibTex | @article{ author = {Khalighfard S and Kalhori MR and Amiriani T and Poorkhani A and Khori V and Esmati E and Lashkari M and Najafi A and Alizadeh AM}, title = {A Systematic Approach Introduced Novel Targets in Rectal Cancer by Considering Mirna/Mrna Interactions in Response to Radiotherapy}, journal = {Cancer Biomarkers}, volume = {33}, number = {1}, pages = {97-110}, year = {2022} } |
RIS | TY - JOUR AU - Khalighfard S AU - Kalhori MR AU - Amiriani T AU - Poorkhani A AU - Khori V AU - Esmati E AU - Lashkari M AU - Najafi A AU - Alizadeh AM TI - A Systematic Approach Introduced Novel Targets in Rectal Cancer by Considering Mirna/Mrna Interactions in Response to Radiotherapy JO - Cancer Biomarkers VL - 33 IS - 1 SP - 97 EP - 110 PY - 2022 ER - |